Mega Genomics Ltd. announced a delay in the publication of its 2024 Annual Results and the 2024 Annual Report. The company also postponed its Board meeting and proposed a change of auditor. Trading in the company's shares remains suspended as the group works to fulfill resumption guidance from the Hong Kong Stock Exchange.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.